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Abstract
We show how entropy balancing can be used for transporting experimental treatment effects
from a trial population onto a target population. This method is doubly-robust in the sense
that if either the outcome model or the probability of trial participation is correctly specified,
then the estimate of the target population average treatment effect is consistent. Furthermore,
we only require the sample moments from the target population to consistently estimate the
target population average treatment effect. We compared the finite-sample performance of
entropy balancing with several alternative methods for transporting treatment effects between
populations. We found that entropy balancing is more robust to violations of the positivity
assumption relative to the other methods while remaining efficient in each of the scenarios we
tested. We also examine the results of our proposed method in an applied analysis of the Action
to Control Cardiovascular Risk in Diabetes Blood Pressure (ACCORD-BP) trial transported to
a sample of US adults with diabetes taken from the National Health and Nutrition Examination
Survey (NHANES) cohort.
1 Introduction
In a randomized controlled trial (RCT), the population from which the sample is collected, the
trial population, often differs from the population of interest, the target population. This scenario
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becomes problematic when the true causal effect is heterogeneous, implying the existence of effect
modifying covariates -effect modifiers - which alter the average treatment effect. If the distribution
of the effect modifiers is different in the trial and target populations, the average treatment effect
observed in the trial will likely differ from what would be observed within the target population,
limiting the conclusions that can be drawn from an otherwise well designed study. This issue is par-
ticularly obvious and challenging when the results of two studies conducted for similar indications
and treatments yield conflicting conclusions. For example the Action to Control Cardiovascular
Risk in Diabetes Blood Pressure (ACCORD-BP) trial and the Systolic Blood Pressure Interven-
tion Trial (SPRINT) randomized participants with hypertension to intensive or conventional blood
pressure control targets. ACCORD-BP was limited to diabetes patients while SPRINT excluded
diabetes patients, and only SPRINT found an association of intensive blood pressure control with
several clinically meaningful outcomes (ACCORD Study Group, 2010; SPRINT Research Group,
2015).
This example is one of several that raises the question of how to infer upon the target population
(e.g., the US population) using data from a trial population. The recent literature on the subject
is divided into two scenarios determined by the nature of the trial and target populations, and
the desired causal estimand. If the trial population is nested within the target population, we
can extend the results of an RCT using a sample from the target population in a process called
generalizability. If the target and trial populations are subpopulations drawn from some super
population, then the problem is one of transportability (Figure 1). We will discuss the difference
between these two scenarios in more detail in Section 2.2. The work herein, however, will focus
primarily on the issue of transportability.
Some articles have approached the problem of transportability from the setting in which the
investigator is provided the individual-level data from the trial population along with individual-
level covariate data from the target population (Rudolph and van der Laan, 2017). Another setting
provides the individual-level data from the trial population, but only the covariate sample moments
(e.g., the mean and standard deviation) from the target population (Signorovitch et al., 2010), which
can often be found in a so-called Table 1 throughout the medical literature. A remarkable property
that is often sought while developing estimators for causal inference is called double-robustness
(Bang and Robins, 2005; Kang and Schafer, 2007). In the context of transporting experimental
results, this means that if either the probability of trial participation or the outcome model are
correctly specified, then the resulting average treatment effect estimator is consistent.
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We propose using entropy balancing to solve transportability problems. The procedure is similar
to the causal effect estimators proposed by Signorovitch et al. (2010); Hartman et al. (2015); Zhang
et al. (2016); Phillippo et al. (2018), which all employ convex optimization techniques to estimate
a vector of sampling weights. These sampling weights would otherwise be uniform if the RCT data
were randomly sampled from the target population. The literature on convex optimization in the
context of causal inference has abounded in recent years (Hainmueller, 2012; Imai and Ratkovic,
2014; Wang and Zubizarreta, 2019). Rather than using these methods is to exactly balance the
covariate distributions between the treated and control units within an observational study, convex
optimization techniques applied to transportability are used to estimate weights which balance the
covariate distributions of the trial participants and non-participants. Entropy balancing is flexible in
that it can be applied both when the complete individual-level covariate data are provided and when
only the covariate sample moments of the target population are provided. Furthermore, entropy
balancing can be shown to be doubly-robust for estimating the population average treatment effect
given the complete individual-level covariate data in the context of transportability.
The contents of the article are as follows. In Section 2 we define the notation, setting, and as-
sumptions necessary for transporting experimental results between populations and describe several
existing methods for transportation, including two methods that can be applied in the setting where
we are given only the sample covariate moments of the target population and two methods that
require individual-level covariate data from the target population, one of which is doubly-robust.
In Section 3, we introduce entropy balancing and describe the difference between conducting infer-
ence upon the population average treatment effect versus the sample average treatment effect. In
Section 4 we compare the five methods considered in Sections 2 and 3. We also illustrate through a
secondary simulation how entropy balancing and other methods that do not require individual-level
data from the target population, only allow for inference upon the sample average treatment effect
and not the population average treatment effect. Section 5 concludes with a discussion.
2 Setting and Preliminaries
2.1 Notation and Potential Outcome
Suppose we have two random samples from different populations. For independent sampling units
i = 1, 2, . . . , n, let Si ∈ {0, 1} denote a random sampling indicator. Indexed by {i : Si = 1}, the
trial sample evaluates the efficacy of some treatment on the trial population. The second sample is
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randomly selected from the target population and indexed by {i : Si = 0}. We refer to this sample
as the target sample. We denote n1 =
∑n
i=1 Si, n0 =
∑n
i=1(1− Si), and n = n1 + n0. Both E(·) or
Pr{·} will be evaluated over the superpopulation which is the combined trial and target population.
For i = 1, 2 . . . , n, let Xi ∈ X denote a vector of measured covariates, Yi ∈ < denote the real
valued outcome, and Zi ∈ {0, 1} denote the random treatment assignment. We assume throughout
that Xi contains an intercept term. The probability density function for Xi is denoted f(xi) for xi ∈
X . We assume a potential outcomes framework with a binary treatment (Rubin, 1974) which allows
us to write the observed outcome in terms of the counterfactuals Yi(0) and Yi(1), i = 1, 2, . . . , n.
Yi(0) and Yi(1) correspond to each unit’s outcomes when Zi = 1 and Zi = 0, respectively. The
observed responses are then defined as Yi ≡ ZiYi(1) + (1−Zi)Yi(0). The potential outcomes allow
us to define the target population average treatment effect, τPATE ≡ E[Yi(1) − Yi(0)|Si = 0] and
the target sample average treatment effect
τSATE ≡ 1
n0
∑
{i:Si=0}
Yi(1)− Yi(0).
We also define ρ(Xi) ≡ Pr{Si = 1|Xi} and pi ≡ Pr{Zi = 1}. Recall that in an RCT, pi ∈ (0, 1)
should be constant with respect to Xi.
We denote the population moments of the target covariate distribution as E(Xi|Si = 0) = θ0.
For much of this paper, we will describe methods for transporting experimental results which weight
the responses Yi for i ∈ {i : Si = 1} so that the weighted trial sample moments are the same as
the population moments of the target population (Deville and Sa¨rndal, 1992). We will denote the
sample weights as γ ≡ (γ1, γ2, . . . , γn1). Since θ0 is usually unknown, we will need to make use of
the estimator θˆ0 ≡ n−10
∑
{i:Si=0}Xi. Again, this information often appears in the so-called Table
1 of many publications.
2.2 Assumptions for Transportability
The following assumptions facilitates our ability to transport experimental results onto a target
population. These assumptions are the same as those presented in Rudolph and van der Laan
(2017) and are originally adapted from the work of Bareinboim and Pearl (2013) who use do-calculus
and directed acyclic graphs to establish sufficient conditions which must be satisfied in order for
transportability to be feasible. We also invoke the stable unit treatment value no interference
assumptions.
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Assumption 1 (Mean Exchangeability). Among all individuals in either the trial or target pop-
ulation, the mean of the potential outcomes are exchangeable between samples conditional on the
baseline covariates: E[Yi(1)|Xi, Si = 1] = E[Yi(1)|Xi] and E[Yi(0)|Xi, Si = 1] = E[Yi(0)|Xi].
Assumption 2 (Sampling Positivity). The probability of trial participation, conditioned on the
baseline covariates necessary to ensure Assumption 1, is bounded away from zero and one:
0 < Pr{Si = 1|Xi = xi} < 1 for all xi ∈ X where f(xi|Si = 0) > 0.
Assumption 3 (Strongly Ignorable Treatment Assignment). The potential outcomes among the
trial participants are independent of the treatment assignment given Xi:
[Yi(0), Yi(1)]
T ⊥ Zi|Xi for all i ∈ {i : Si = 1}.
Assumption 3 is a standard assumption in the potential outcomes literature (Rosenbaum and
Rubin, 1983). This assumption can be further simplified in an RCT to assume
{Yi(0), Yi(1)} ⊥ Zi for all i ∈ {i : Si = 1}
since there should be no association between the treatment assignment and the covariates. The
covariate imbalance that requires amelioration in transportability instead appears between Xi and
Si.
As noted previously in the Introduction, there are subtle distinctions between generalizability
and transportability. The main difference occurs with the causal estimand of interest. In trans-
portability, the target estimand is τPATE. For generalizability, the causal estimand of interest is
τATE ≡ E [Yi(1)− Yi(0)]. This is on account of the trial population being nested within the target
population, so the superpopulation and the target population are identical. Under our notation,
generalizability further assumes that the units {i : Si = 0} are sampled from the target population
and the complement of the trial population. As a result, we would need to rewrite Assumption 2
for generalizability to state
0 < Pr{Si = 1|Xi = xi} < 1 for all xi ∈ X where f(xi) > 0.
We avoid this setup to the problem and instead focus on methods developed for transportability
and inference on τPATE.
In addition to Assumptions 1-3, we require the following assumptions to establish the double-
robustness property of entropy balancing. We also use these assumptions to establish the con-
sistency of some of the other methods we describe in Section 2.3 when regression methods are
employed.
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Assumption 4 (Conditional Linearity). The expected value of the potential outcomes, conditioned
on Xi, is linear across the span of the covariates. That is E[Yi(1)|Xi] = XTi α and E[Yi(0)|Xi] =
XTi β for all i = 1, 2, . . . , n and α,β ∈ <m.
Assumption 5 (Linear Conditional Log-Odds). The log-odds of trial participation are linear across
the span of the covariates. That is logit[ρ(Xi)] = X
T
i λ for all i = 1, 2, . . . , n and some λ ∈ <m.
2.3 Alternative Methods for Transportability
In this section we present four different methods for transporting experimental results to estimate
τPATE. For each method, we assume Assumptions 1-3 are given. The first method weights responses
of the trial sample with the inverse odds of sampling (Westreich et al., 2017; Dahabreh et al., 2019).
Define the inverse odds of sampling weights as
γˆPSi =

1−ρˆ(Xi)
ρˆ(Xi)pˆi
, when Si = 1, Zi = 1
1−ρˆ(Xi)
ρˆ(Xi)(1−pˆi) , when Si = 1, Zi = 0
0, when Si = 0
where pˆi is a consistent estimator of the probability of treatment and ρˆ(Xi) is a consistent estimator
of the probability of trial participation. The target population average treatment effect is then
estimated by computing
τˆIOSW =
∑
{i:Si=1}
γˆPSi ZiYi∑
{i:Si=1} γˆ
PS
i Zi
−
∑
{i:Si=1}
γˆPSi (1− Zi)Yi∑
{i:Si=1} γˆ
PS
i (1− Zi)
.
If Assumption 5 is given, we may use logistic regression to consistently estimate ρˆ(Xi). A consistent
estimator for ρ(Xi) by extension renders τˆIOSW consistent for τPATE.
Another proposed solution is to fit a consistent model of the conditional means for the potential
outcomes with the sample data; µ1(Xi) ≡ E[Yi(1)|Xi, Si = 1] and µ0(Xi) ≡ E[Yi(0)|Xi, Si = 1].
We will refer to this method as the outcome modeling (OM) approach. The consistent estimators
are denoted as µˆ1(Xi) and µˆ0(Xi), respectively. Under Assumption 1, τPATE can be estimated by
solving for
τˆOM =
1
n0
∑
{i:Si=0}
µˆ1(Xi)− µˆ0(Xi).
In the causal inference literature, this method follows the framework for computing causal effects
known as g-computation (Robins, 1986). If we are additionally given Assumption 4, we can also
estimate τPATE with the OM approach if we are only given θˆ0 instead of Xi for all i ∈ {i : Si = 0}.
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To do so, we would regress Yi on Xi for all {i : Si = 1, Zi = 1} and {i : Si = 1, Zi = 0} to get αˆ
and βˆ, respectively. We then observe
τˆOM = θˆ
T
0
(
αˆ− βˆ
)
.
The OM approach and the inverse odds of sampling weights may be combined using targeted
maximum likelihood estimation (TMLE). The algorithm is described in Rudolph and van der Laan
(2017) and proceeds as follows for an approximately Gaussian response variable. First, the initial
estimates of µˆ1(Xi) and µˆ0(Xi) are fit using the trial sample data. We then update the predictions
of the potential outcomes on the trial sample with
µ˜0(Xi) = µˆ0(Xi) + ˆ0(1− Zi)γˆPSi
µ˜1(Xi) = µˆ1(Xi) + ˆ1Ziγˆ
PS
i .
(1)
The estimates of 0 and 1 are obtained using standard regression techniques with µˆ0(Xi) and
µˆ0(Xi) serving as offsets for all i = 1, 2, . . . , n. The estimator of τPATE solves for
τˆTMLE =
1
n0
∑
{i:Si=0}
µ˜1(Xi)− µ˜0(Xi) (2)
similar to the OM approach. Equation (2) is doubly-robust for estimating τPATE in the sense that if
either the model for the probability of sampling or the model of the potential outcomes is consistent,
then τˆTMLE is also consistent. Therefore, if logistic regression is used to estimate ρ(Xi), and linear
regression is used to estimate µ1(Xi) and µ0(Xi), then if either Assumptions 4 or 5 hold, τˆTMLE
will be consistent for estimating τPATE. TMLE requires individual-level covariate data for some of
the components in (1) and (2). Some alterations may be made to these estimators so that TMLE
can work in the setting where we are only provided the target sample covariate moments. This
inquiry is outside the scope of this paper, though more details are provided in discussion.
Similar to the OM approach, the method of moments (MOM) estimator first proposed by
Signorovitch et al. (2010) and later implemented with some variation by Phillippo et al. (2018)
only requires the target sample moments of the covariates to estimate τPATE. For this solution,
denote X¯i = (2Zi − 1,Xi) and θ˜0 = (0, θˆ0). The method of moments estimator first solves the
Lagrangian dual problem
λˆ = arg max
λ∈<m+1
n∑
i=1
[
− exp (−X¯Ti λ)− θ˜T0 λ] , (3)
which in turn is used to estimate the sampling weights, γˆMOMi = exp
(
−X¯Ti λˆ
)
. We can then use
a Horvitz-Thompson type estimator similar to the inverse odds of sampling weights to estimate
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τPATE,
τˆMOM =
∑
{i:Si=1}
γˆMOMi (2Zi − 1)Yi∑
{i:Si=1} γˆ
MOM
i Zi
.
In Signorovitch et al. (2010), Assumptions 1-3 along with Assumption 5, are sufficient to establish
the consistency of τˆMOM for τPATE.
3 Entropy Balancing
We now present a method for estimating sampling weights to transport experimental results using
entropy balancing. Entropy balancing is similar to the method of moments estimator presented in
Section 2.3 with a subtle modification to the estimation procedure. Instead of solving (3), entropy
balancing first solves the following separable Lagrangian dual problems to get
λˆ0 = arg max
λ∈<m
∑
{i:Si=1}
{
− exp [−(1− Zi)XTi λ]− θˆT0 λ} and
λˆ1 = arg max
λ∈<m
∑
{i:Si=1}
[
− exp (−ZiXTi λ)− θˆT0 λ] . (4)
The empirical sampling weights are subsequently found with
γˆEBi = exp
[
−(1− Zi)XTi λˆ0 − ZiXTi λˆ1
]
for all i ∈ {i : Si = 1}. (5)
The estimator for τPATE using the entropy balancing weights is the same Horvitz-Thompson type
estimator used by the method of moments and the inverse odds of sampling weighting approaches,
τˆEB =
∑
{i:Si=1}
γˆEBi (2Zi − 1)Yi∑
{i:Si=1} γˆ
EB
i Zi
. (6)
Notice that the treatment-specific covariate distributions are balanced instead of the combined
covariate distribution as with (3). This alteration was inspired by Chan et al. (2016) and allows us
to establish τˆEB as doubly-robust. This property about entropy balancing is examined more closely
in the Appendix.
There are a few reasons why we use the relative entropy over other criterion distance functions
for transporting experimental results. The first is due to the resemblance of (5) to the odds of
sampling under Assumption 5. This has been noted in several other articles (Signorovitch et al.,
2010; Zhao and Percival, 2017). Another reason for using the relative entropy is the guarantee
that the estimated sampling weights will always be positive. Another recommendation might be
to construct a Lagrangian dual using the Euclidean distance as the criterion function to get (4).
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However, the support for the Euclidean distance is the real numbers, implying that negative weights
are feasible in such a setup. Adding the necessary constraint that γi > 0 for all i = 1, 2, . . . , n makes
the optimization problems in (4) more difficult to solve.
Consider the setting where we are provided only the sample covariate moments from the target
sample. Assuming that θˆ0 is fixed results in an inflated Type I error rate for inferences of τPATE.
The one exception to this rule is when θˆ0 = θ0 with zero variability. In other words, we would
need to estimate θˆ0 over the entire target population. If we are provided individual-level covariate
data from the target sample, then we may derive a variance estimator for estimates of τPATE as
opposed to τSATE. Despite this shortrfall, note that the estimators (4) - (6) are consistent for τPATE
in either setting. The same rule applies for both the OM approach and the MOM estimator since
neither of these methods necessarily require the complete individual-level covariate data. A more
concrete demonstration of this phenomenon is shown in Section 4.2.
4 Numerical Examples
4.1 Simulation Study
In this section we present a simulation study to better understand the performance of entropy
balancing compared with the alternative methods illustrated in Section 2.3. We consider four
experimental scenarios that test the consistency and efficiency of the estimators on finite-samples
by altering the data generating processes.
The first scenario establishes a baseline. For i = 1, 2, . . . , n, let (Xi0|Si = 0) ∼ N (−1, 2),
(Xi1|Si = 0) ∼ Bin(1, 0.6), (Xi2|Si = 0) ∼ N (0, 1), and (Xi3|Si = 0) ∼ Bin(1, 0.5). Let (Xi0|Si =
1) ∼ N (1, 2), (Xi1|Si = 1) ∼ Bin(1, 0.4), (Xi2|Si = 1) ∼ N (0, 1), and (Xi3|Si = 1) ∼ Bin(1, 0.5).
We generate the treatment assignment by sampling Zi ∼ Bin(1, 0.5). The conditional mean of the
potential outcomes are constructed as
µ0(Xi) = 10− 2Xi0 −Xi1 +Xi2 + 2Xi3 and
µ1(Xi) = µ0(Xi) + 2 + 2Xi0 −Xi1 +Xi2 − 2Xi3.
(7)
Gaussian potential outcomes for each experimental scenario are generated by sampling Yi(0) ∼
N [µ0(Xi), σ2] and Yi(0) ∼ N [µ1(Xi), σ2], with the observed outcome determined by Yi = ZiYi(1)+
(1− Zi)Yi(0) for each i = 1, 2, . . . , n. We discard the n0 values of Yi and Zi for all i ∈ {i : Si = 0}.
We will refer to this set of conditions with the label “baseline”.
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For the scenario labeled “interaction”, we test the effect of ignoring outcome modifying inter-
actions in the causal effect estimators. Using the same covariate distributions from the baseline
scenario, let
µ0(Xi) = 10− 2Xi0 −Xi1 +Xi2 + 2Xi3 + 2Xi0Xi1 −Xi0Xi3 and
µ1(Xi) = µ0(Xi) + 2 + 2Xi0 −Xi1 +Xi2 − 2Xi3 −Xi0Xi1 + 2Xi0Xi3.
(8)
In the scenarios labeled “positivity”, we increase the difference between the two covariate distri-
butions by modifying (Xi0|Si = 0) ∼ N (1, 1), (Xi1|Si = 0) ∼ Bin(1, 0.3), and (Xi1|Si = 1) ∼
Bin(1, 0.7). This alteration will test the sensitivity of each method to slight violations of As-
sumption 2. Finally, for the scenario labeled “sparse”, we provide each method an additional
set of covariates that do not affect the responses. The potential outcomes are still determined
by using (7), yet the weighting estimators must also accommodate the additional covariates of
(Xir|Si = 0) ∼ (Xi(r−4)|Si = 1) and (Xir|Si = 1) ∼ (Xi(r−4)|Si = 0) for r ∈ {4, 5, 6, 7}. In addition
to varying the scenarios, we also vary n0 ∈ {500, 1000} and n1 ∈ {200, 1000}, creating 16 different
conditions for which we will generate 1000 replications.
We report the empirical mean and Monte Carlo standard error of the average treatment effect
estimates across the 1000 iterations for each scenario. The five methods we compare are:
1. (IOSW) Inverse Odds of Sampling Weights;
2. (OM) Outcome Model;
3. (TMLE) Targeted Maximum Likelihood Estimation;
4. (MOM) Method of Moments;
5. (EB) Entropy Balancing.
The results of the experiment are summarized in Table 1. A visual comparison for a subset
of the results featured in Table 1 where n1 = 1000 and n0 = 1000 appear in the boxplots of
Figure 2. Each method produces consistent estimates under the baseline scenario. However, each
method also has its short-comings. First, we can see that IOSW produce highly variable estimates
in cases where the positivity assumption (Assumption 2) is violated. On the other hand, the OM
approach is biased when there are unspecified interactions attributable to the average treatment
effect. TMLE, MOM, and EB all appear to produce unbiased estimates of the average treatment
effect in every scenario. However, we can see in Table 1 that EB had either the same or smaller
10
Monte Carlo standard error among these three methods for every scenario. The OM approach had
the smallest standard error, other than in the scenarios where there are unspecified interactions.
We do observe a downside to entropy balancing, however. In the sparse scenario, the number of
models that convergence decreases considerably. When n1 = 200 and n0 = 500, entropy balancing
was only able to find a solution in 64.2% of the iterations. When n1 = 200 and n0 = 1000 we
observe a 66.0% rate of convergence. Otherwise, the algorithm converged in each iteration for
every other scenario.
4.2 Coverage Probabilities of the PATE and SATE
Consider the baseline scenario in the previous set of simulations. Using the individual-level data
from the trial sample, and the target sample covariate moments, we demonstrate how inferences
for τPATE have an inflated Type I error. We do so by finding the empirical coverage probability
of both τSATE and τPATE with entropy balancing and outcome modeling approaches. The sample
variance is obtained using a robust sandwich variance estimator in both methods. The coverage
probability is obtained by averaging over the indicator variable generated by whether the resulting
confidence interval about the average treatment effect estimate covers either τSATE or τPATE at
each iteration. This will demonstrate why entropy balancing can only be used to infer upon the
sample average treatment effect instead of the population average treatment effect unless the entire
individual-level data about the covariates in both the target and trial samples is available. For
this simulation experiment, we let n0 ∈ {1000, 10000} and n1 ∈ {1000, 10000}. We use such large
numbers to ensure the accuracy of the robust variance estimator.
The results in Table 2 show how modifying n1 and n0 affects the coverage probabilities for τSATE
and τPATE for the setting where we are given the target sample covariate moments. Observe that the
coverage probability of τSATE is dependent on n1 alone - as n1 increases, the coverage probabilities
increase. The coverage probability of τPATE, on the other hand, appears to be dependent on the
ratio between n0 and n1. For inference on τPATE, we see the best results occur when n1 is small
relative to n0. When n1 = 1000 and n0 = 10000, the variation of θˆ has less impact on the total
variance, producing the best results. In contrast, when n1 = 10000 and n0 = 10000, the variation
of θˆ has a greater impact, resulting in a decreased probability of coverage. This observation is
only compounded in cases where n1 > n0. This leads us to believe that n1 needs to be sufficiently
large while also remaining small compared to n0 in order to be effective for inferring on the τPATE.
When we adjust the sandwich estimator to incorporate individual-level covariate data from the
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target sample, we see that the accuracy of coverage probability is now tied to the total sample size
n = n0 + n1, which is typical for robust variance estimators as they are derived under asymptotic
conditions.
4.3 Transporting Results of ACCORD-BP study to the US Population
In our applied example, we transport four-year post randomization risk difference estimates of
total mortality observed in the ACCORD-BP trial (ACCORD Study Group, 2010) to a sample of
US diabetes patients drawn from the NHANES cohort. A similar analysis using inverse odds of
sampling weights to compare the hazard rates of the treated and controls over the entire follow-up
period is described in Berkowitz et al. (2018). We use two methods for transporting the results
of ACCORD-BP to NHANES - IOSW and EB. Furthermore, using entropy balancing we provide
confidence intervals about the target sample average treatment effect and the target population
average treatment effect. Recall that the former estimand does not require any individual-level
data from the NHANES sample. Table 3 shows covariates balanced between ACCORD-BP and
NHANES, their unweighted sample covariate moments from the NHANES and from the ACCORD-
BP data, and the subsequent weighted covariate sample moments of the ACCORD-BP sample after
balancing. The covariate sample moments after EB weighting consistently matched the NHANES
sample more closely than after IOSW weighting (Table 2).
The ACCORD-BP study originally found an increase in the four-year mortality of 0.59% [95%
CI:(-0.75%, 1.93%)] in the intensive treatment group. The covariates distributions differ between
the ACCORD-BP and NHANES samples (Table 2), reflecting that ACCORD trial eligibility criteria
focused on those with relatively long duration of diabetes and high prevalence of cardiovascular
risk factors. After weighting the ACCORD-BP responses with inverse odds of sampling weights
estimated with maximum likelihood, the estimated risk difference on the NHANES population is
-1.35% [95% CI: (-3.5%, 0.8%)]. Using EB, we observe a risk difference of -0.04% [95% CI: (-1.80%,
1.71%)] where the confidence interval corresponds to the NHANES sample average treatment effect.
The 95% confidence interval for the population average treatment effect is (-1.94%, 1.86%) when
using the individual level covariate data from the NHANES sample.
Though the total mortality is insignificant at a 0.05 level of significance, regardless of method,
we see changes in the risk difference estimate. The original analysis found an increase in mortality
among the intensively treated patients. IOSW weights yielded a decreased total mortality among
intensively treated patients in the NHANES population, while EB weights yielded a nearly null
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result. These differences seem to indicate the presence of effect modifiers contributing to the effect
of blood pressure treatment intensity on mortality.
5 Discussion
In this article we have described a doubly-robust method for transporting experimental results
borrowed from the entropy optimization literature. This method may operate in two settings -
when we are presented with the complete individual-level data of the trial sample and either the
individual-level covariate data or the covariate sample moments of the target sample. The distinc-
tion between the two settings amounts to inferring upon the target population average treatment
effect versus the target sample average treatment effect. We showed entropy balancing to be an ef-
ficient causal effect estimator in finite-samples through simulation. We also compared two methods
for transporting the ACCORD-BP study to the NHANES population. These numerical examples
demonstrate some of the practicable implications of our work.
The drawback to using entropy balancing for transportability is with the algorithm’s rate of
convergence. In small samples, the probability that a feasible weighting solution exists decreases.
One solution applied to covariate balance problems in Wang and Zubizarreta (2019), which uses in-
equality constraints to mitigate treatment group heterogeneity, may be useful in a high-dimensional
setting. There may also be a way to incorporate the method of moment balancing weights into
the TMLE framework by substituting γˆMOM for γˆPS in (2). This could eventually set up a TMLE
estimator that can operate in the setting where we do not have any individual-level data from the
target population.
Future work will address two additional data settings not evaluated here. First, the setting
where the target sample contains data from a sencond randomized experiment, including both the
individual-level outcome and the treatment assignment. The process of combining experiments,
termed as data fusion, is beyond what we discuss in this paper but is nevertheless an important
problem which we would like to approach with entropy balancing in future research. A second
direction for future work is to examine methods for transportability between two observational
samples, rather than assuming availability of randomized clinical trial data for the trial sample. In
this situation, we would also need to model the probability of treatment within the the observational
study representing the “trial” sample. We might also seek to relax assumptions 4 and 5 using a
nonparametric setup to the problem similar to the sieve approach of Chan et al. (2016) but instead
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applied to transportability.
In summary, entropy balancing provides an approach to transportability that is flexible regard-
ing the applicable data settings and exhibits double robustness in specific scenarios. In particular,
entropy balancing yields more precise effect estimates across a range of simulation scenarios when
the target population is large than alternative methods using only covariate sample moments from
the target population.
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A Transporting Inferences using Entropy Balancing
Under Assumption 4, Zhang et al. (2016) describe another consistent estimator for τPATE as
τˆDR =
∑
{i:Si=1}
γˆPSi Zi[Yi − µˆ1(Xi)]∑
{i:Si=1} γˆ
PS
i Zi
−
∑
{i:Si=1}
γˆPSi (1− Zi)[Yi − µˆ0(Xi)]∑
{i:Si=1} γˆ
PS
i (1− Zi)
+
1
n0
∑
{i:Si=0}
[µˆ1(Xi)− µˆ0(Xi)] .
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Suppose µˆ0(Xi) = X
T
i βˆ → µ∗0(Xi), µˆ1(Xi) = XTi αˆ→ µ∗1(Xi), and µ∗0(Xi), µ∗1(Xi) denote the true
means of the potential outcomes. To show that τˆEB is a consistent estimator for τPATE, we show
the algebraic equivalency of τˆEB and τˆDR when we substitute γˆ
PS with γˆEB into τˆDR. Observe that
Xi1 = 1 for all i ∈ {i : Si = 1} and θˆ01 = 1 then
∑
{i:Si=1} γˆiZi =
∑
{i:Si=1} γˆi(1− Zi) = n1. Given
Assumption 4, we can expand the difference between τˆDR and τˆEB to get
τˆEB − τˆDR = 1
n1
∑
{i:Si=1}
[
γˆEBi Ziµˆ1(Xi)− γˆEBi (1− Zi)µˆ0(Xi)
]− 1
n0
∑
{i:Si=1}
[µˆ1(Xi)− µˆ0(Xi)]
=
1
n1
∑
{i:Si=1}
[
γˆEBi ZiX
T
i αˆ− θˆ
T
0 αˆ− γˆEBi (1− Zi)XTi βˆ + θˆ
T
0 βˆ
]
=
1
n1
∑
{i:Si=1}
{(
γˆEBi ZiX
T
i − θˆ
T
0
)
αˆ−
[
γˆEBi (1− Zi)XTi − θˆ
T
0
]
βˆ
}
= 0
(9)
If we suppose that logit[ρ∗(X)] = logit[ρ∗(X;λ∗)]XTλ∗ for λ∗ ∈ <m, then the entropy balancing
approach to transporting experimental results as implemented with (4), (5), and (6) is consistent
for τSATE and τPATE. The proof of this is via a standard application of m-estimation theory. Let
λˆ0 and λˆ1 be determined by (4) and τˆ by (6). For estimating the variance of the estimator for
τPATE requires the trivial estimating equation
δ(S,X;θ0) = (1− S)(X− θ0).
Observe that
∑n
i=1 Si(Xi− θˆ0) = 0. In the case of the SATE, we would ignore ζ and treat θ0 = θˆ0
as though it were fixed and known. Next, we define the following estimating equations for λ0 and
λ1 as
ζ0(S,X, Z;λ0,θ0) = S(1− Z) exp
(−XTλ0) (X− θ0) and
ζ1(X, Z;λ1,θ0) = SZ exp
(−XTλ1) (X− θ0) .
These equations correspond to the first order conditions derived from (4). Notice that
n∑
i=1
ζ0(Si,Xi, Zi; λˆ0, θˆ0) = 0m and
n∑
i=1
ζ1(Si,Xi, Zi; λˆ1, θˆ0) = 0m.
Finally, we require the estimating equation for τ which is defined as
ψ(S,X, Y, Z;λ0,λ1, τ) = S
[
Z exp
(−XTλ1) [Y (1)− τ ]− (1− Z) exp (−XTλ0)Y (0)] .
Again, notice that
n∑
i=1
ψ(Si,Xi, Yi, Zi; λˆ0, λˆ1, τˆEB) = 0.
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We also write η =
(
θT0 ,λ
T
0 ,λ
T
1
)T
and
ξ(S,X, Z;η) ≡ [δ(S,X;θ0)T , ζ0(S,X, Z;λ0,θ0)T , ζ1(X, Z;λ1,θ0)T ]T .
For the sake of compactness, we sometimes omit the parameters that characterize these estimating
equations while using this function notation.
Remark 1. If the desired estimand is τSATE instead, we would exclude the estimating equation δ(·)
from ξ and θ0 from η since this change would amount to assuming θ0 = θˆ0 is fixed and known.
Remark 2. When the target sample is drawn from the target population with a known weighting
scheme, lets say qi for all i ∈ {i : Si = 0}, we would instead use the marginal estimator θˆ0 ≡(∑
{i:Si=0} qi
)−1∑
{i:Si=0} qiXi. We also modify the estimating equation for θ0 to be
δ(S,X;θ0) = (1− S)(qX− θ0).
According to Kennedy (2016), the efficient influence function for τPATE can be written so that
φ(S,X, Y, Z) ≡ ψ(S,X, Y, Z)− E
[
∂ψ(X, Y, Z)
∂η
]T {
E
[
∂ξ(S,X, Z)
∂η
]}−1
ξ(S,X, Z)
which can be used to show
τˆEB − τPATE = 1
n1
∑
{i:Si=1}
φ(Si,Xi, Yi, Zi;η
∗, τPATE) + o
(
n−1/2
)
(10)
where η∗ =
[
(θ∗0)
T , (λ∗0)
T , (λ∗1)
T
]T
. Thus, we only need to show that the expected value of δ, ζ0,
ζ1, and ψ equal zero in order to prove consistency of τˆEB. It is trivial to show that E[δ(S,X;θ
∗
0)] =
E [X− θ∗0|S = 0] = 0m. For ζ0 and ζ1, note that given Z ⊥ X as is typical with an RCT, we have
E[g(X)|S = 0, Z = 0] = E[g(X)|S = 0, Z = 1] = E[g(X)|S = 0]
for some function g : <m → <. Furthermore, we know that E{[1 − ρ(X)]g(X)} ∝ E [g(X)|S = 0]
and [(1− Z)g(X)] = (1− pi) [g(X)|Z = 0]. Thus, we have
E [ζ0(S,X, Z;λ
∗
0,θ
∗
0)] = E
{
E
[
S(1− Z) exp (−XTλ∗0) (X− θ∗0)∣∣X]}
= (1− pi)E
[
exp
(−XTλ∗0)
1 + exp (−XTλ∗) (X− θ
∗
0)
∣∣∣∣∣Z = 0
]
= (1− pi)E
{
exp
(−XTλ∗0)
1 + exp (−XTλ∗) [X− E(X|S = 0)]
}
,
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which we note can only equal zero if exp(XTλ∗0) = c0 exp(XTλ
∗) since
E
{
exp
(−XTλ∗)
1 + exp (−XTλ∗) [X− E(X|S = 0)]
}
∝ E [X− E(X|S = 0)|S = 0] = 0.
A similar result can be derived for E [ζ1(S,X, Z;λ
∗
1,θ
∗
0)] where we once again recognize that it is
necessary for exp(XTλ∗1) = c1 exp(XTλ
∗). We can also take the expectation of ψ to get
E [ψ(S,X, Y, Z;λ∗0,λ
∗
1, τPATE)] = E
(
E
{
SZ exp
(−XTλ∗1) [Y (1)− τPATE]∣∣X})
− E{E [(1− Z) exp (−XTλ∗0)Y (0)∣∣X]}
= pic1E
{
exp
(−XTλ∗)
1 + exp (−XTλ∗) [µ1(X)− τPATE]
∣∣∣∣∣Z = 1
}
− (1− pi)c0E
[
exp
(−XTλ∗)
1 + exp (−XTλ∗)µ0(X)
∣∣∣∣∣Z = 0
]
∝ c1piE [µ1(X)− τPATE|S = 0]− c0(1− pi)E [µ0(X)|S = 0] .
(11)
Here we provide a values for c1 = pi
−1 and c0 = (1 − pi)−1 so that (11) can evaluate to zero. We
then simply apply the weak law of large numbers to (10) to conclude τˆEB →p τPATE. Note that the
variance estimator for this problem is the empirical version of Σ ≡ E [φ(S,X, Y, Z)2] since, by the
classic central limit theorem,
√
n(τˆEB − τPATE)→d N (0,Σ).
B Simulation Code
Code for reproducing the simulation experiment conducted in Section 4.1 is available at the following
address: https://github.com/kevjosey/transport-sim. Code is also available for replicating
the illustrative experiment originally analyzed in Berkowitz et al. (2018) upon request from the
authors.
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Tables and Figures
n0 n1 Scenario PATE IOSW OM TMLE MOM EB
500 200 baseline -0.4 -0.31 (0.91) -0.39 (0.51) -0.40 (0.60) -0.40 (0.74) -0.40 (0.59)
500 200 interaction -0.8 -0.75 (1.51) -1.23 (0.77) -0.84 (0.96) -0.89 (1.28) -0.86 (0.80)
500 200 positivity -0.3 -3.01 (1.94) -0.29 (0.56) -0.29 (0.65) -0.26 (0.82) -0.28 (0.70)
500 200 sparse -0.4 -0.18 (1.36) -0.41 (0.64) -0.47 (1.43) -0.43 (1.19) -0.36 (0.93)
500 1000 baseline -0.4 -0.40 (0.43) -0.42 (0.28) -0.42 (0.31) -0.43 (0.36) -0.42 (0.31)
500 1000 interaction -0.8 -0.75 (0.7) -1.18 (0.39) -0.77 (0.48) -0.80 (0.63) -0.79 (0.42)
500 1000 positivity -0.3 -2.25 (0.95) -0.30 (0.26) -0.30 (0.30) -0.31 (0.40) -0.31 (0.33)
500 1000 sparse -0.4 -0.32 (0.71) -0.39 (0.34) -0.40 (0.55) -0.39 (0.56) -0.39 (0.44)
1000 200 baseline -0.4 -0.30 (0.91) -0.41 (0.52) -0.41 (0.61) -0.42 (0.73) -0.41 (0.61)
1000 200 interaction -0.8 -0.74 (1.49) -1.22 (0.75) -0.86 (1.00) -0.87 (1.26) -0.87 (0.78)
1000 200 positivity -0.3 -3.54 (2.19) -0.30 (0.57) -0.30 (0.66) -0.31 (0.84) -0.30 (0.71)
1000 200 sparse -0.4 -0.21 (1.38) -0.4 (0.61) -0.39 (1.34) -0.39 (1.15) -0.39 (0.94)
1000 1000 baseline -0.4 -0.37 (0.41) -0.39 (0.24) -0.40 (0.28) -0.39 (0.33) -0.40 (0.28)
1000 1000 interaction -0.8 -0.8 (0.71) -1.21 (0.37) -0.80 (0.46) -0.81 (0.61) -0.82 (0.39)
1000 1000 positivity -0.3 -2.81 (1.04) -0.29 (0.26) -0.29 (0.28) -0.28 (0.39) -0.29 (0.32)
1000 1000 sparse -0.4 -0.32 (0.71) -0.39 (0.30) -0.38 (0.53) -0.39 (0.50) -0.38 (0.42)
Table 1: Average estimate of τtextPATE with corresponding Monte Carlo standard errors.
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Without Individual Level Data
With Individual
Level Data
n0 n1 EB SATE EB PATE OM SATE OM PATE EB PATE
500 1000 0.918 0.858 0.941 0.850 0.947
500 10000 0.946 0.536 0.959 0.474 0.951
1000 1000 0.927 0.905 0.944 0.900 0.944
1000 10000 0.948 0.668 0.959 0.615 0.941
10000 1000 0.920 0.921 0.950 0.946 0.925
10000 10000 0.938 0.904 0.937 0.895 0.936
Table 2: Coverage Probabilities of τSATE and τPATE using Entropy Balancing and Outcome Mod-
eling Techniques.
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Variables NHANES ACCORD-BP IOSW ACCORD-BP EB ACCORD-BP
Baseline age, yrs 59.65± 13.70 62.84± 6.74 61.50± 6.66 59.61± 6.91
Female 48.9 47.1 48.0 48.9
Race/Ethnicity
Non-Hispanic white 62.6 58.7 51.6 62.5
Non-Hispanic black 15.2 24.0 19.6 15.2
Hispanic 15.2 6.8 22.3 15.2
Asian/multi/other 7.0 10.5 6.5 7.1
Insurance 86.8 85.0 84.6 86.6
Smoking status
Never 51.4 44.6 52.9 51.4
Former 33.1 42.6 30.9 33.1
Current 15.5 12.8 16.2 15.5
Education
Less than HS 25.7 16.3 30.9 25.7
HS diploma 27.1 27.0 26.4 27.1
Some college 29.3 32.4 26.5 29.3
College diploma or higher 17.9 24.3 16.2 17.9
History of CHF 7.7 4.2 11.0 7.7
History of MI 10.5 13.6 11.4 10.5
History of stroke 7.9 6.4 7.5 7.8
Years with diabetes 7.49± 9.20 10.88± 7.83 10.05± 7.26 7.50± 6.51
BMI, kg/m2 32.80± 7.31 32.10± 5.47 32.07± 5.52 32.80± 5.78
SBP, mm Hg 130.05± 19.15 139.33± 15.61 133.94± 14.42 129.67± 13.98
DBP, mm Hg 69.50± 12.96 75.86± 10.28 71.53± 9.57 69.44± 9.55
HDL, mg/dl 49.11± 13.46 46.049± 13.68 51.60± 17.24 49.08± 17.72
LDL, mg/dl 103.83± 36.03 110.70± 36.52 105.42± 31.33 103.59± 33.31
Triglycerides, mg/dl 148.93± 76.13 193.36± 174.21 125.40± 68.01 147.21± 95.52
FPG, mg/dl 151.88± 54.62 174.81± 57.66 171.54± 57.47 151.11± 47.3
HbA1c, % 7.16± 1.64 8.34± 1.09 7.94± 0.95 7.16± 0.75
Estimated GFR, ml/min 87.46± 28.11 91.64± 29.83 84.99± 21.16 87.31± 22.66
Urine albumin to creatinine ratio 75.44± 481.68 93.84± 333.81 105.89± 427.60 45.32± 204.57
Table 3: Values are mean ± SD or %. Means and percentages for NHANES are nationally repre-
sentative using NHANES sampling weights.
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Figure 1: A - Diagram of Generalizability; B - Diagram of Transportability
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Figure 2: Estimates of the population average treatment effects over the 1000 iterations of the
simulation study in Section 4.1
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